Approval · Notice of Compliance 16077 · 2014
TEVA-EZETIMIBE: Notice of Compliance 16077
Issued September 15, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16077
- Date
- September 15, 2014
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Changes to the manufacturing process
- Therapeutic class
- Cholesterol absorption inhibitor
- Canadian reference product
- EZETROL (Merck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-EZETIMIBE | Not yet assigned | — |
Medicinal ingredients
- EZETIMIBE 10 MG per TAB